Amino acid-based therapy for pulmonary fibrosis: L-Leucine decreases miR-34 expression, increases Sirtuin-1 expression, suppresses tumor suppressor p53 acetylation, prevents apoptosis in Alveolar epithelial cell (AEC), and improves pulmonary fibrosis via down regulation of its target gene, 14/March/2017, 11.34 am

Natural product-derived therapy for Metastatic cancers: Oleic acid, found in Safflower, olive, canola, Hazelnut, sunflower oils, Avacados, almond and sunflower among others, decreases the expression of PPM22 and inhibits migration, invasion and metastasis of cancer cells via up regulation of its target gene, 13/March/2017, 11.42 pm
March 13, 2017
Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: Ursolic acid, isolated from Mirabilis Jalapa, Ocimum sanctum, and Apple peels among others, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 14/March/2017, 1.07 pm
March 14, 2017
Show all

What we say

Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Amino acid-based therapy for pulmonary fibrosis: L-Leucine decreases miR-34 expression, increases Sirtuin-1 expression, suppresses tumor suppressor p53 acetylation, prevents apoptosis in Alveolar epithelial cell (AEC), and improves pulmonary fibrosis via down regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) Idiopathic pulmonary disease (IPD)/Idiopathic pulmonary fibrosis (IPF)  is a progressive degenerative disease of the lung, with debilitating consequences; (2) drugs that are currently used to treat IPF are ineffective; and (3) 6.8-16.3 per 100,000 persons suffer from  Idiopathic pulmonary disease, there is an urgent need to find: (i) a way to induce regeneration of lung cells in pulmonary fibrosis patients; (ii) side-effect-free natural product-based drug; and (iii) a way to effectively treat and cure PF


From research findings to therapeutic opportunity

This study suggests, for the first time, that Leucine, by increasing the expression of its target gene, it may: (1) decrease the expression of p53 and its target gene miR-34a; (2) increase the expression of longevity-protein Sirtuin-1; (3) suppress p53 acetylation; (4) inhibit urokinase-type plasminogen activator (uPA) and the uPA receptor expression in AECs (Alveolar epithelial cells); (5) prevent apoptosis in AECs; and (6) inhibit the development and progression of pulmonary fibrosis. Thus, pharmacological formulations encompassing “Leucine or its analogues either alone or in combination with other drugs may be used to treat pulmonary fibrosis (Fig.1).

 

Image result for leucine

Figure1. Amino acid Leucine protects  against Pulmonary fibrosis via down regulation of p53 and its target gene miR-34a


Details of the research findings

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How Leucine decreases miR-34 expression to improve pulmonary fibrosis

Amount: $100#

# Research cooperation


References

CitationBoominathan, L., Amino acid-based therapy for pulmonary fibrosis: L-Leucine decreases miR-34 expression, increases Sirtuin-1 expression, suppresses tumor suppressor p53 acetylation, prevents apoptosis in Alveolar epithelial cell (AEC), and improves pulmonary fibrosis via down regulation of its target gene, 14/March/2017, 11.34 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com

Courtesy: When you cite, kind drop us a line at admin@genoemdiscovery.org

 

# Research cooperation

Comments are closed.